Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

trialsTrialActive

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

A phase 1/2 trial of PM8002 in triple-negative breast cancer, run by Biotheus Inc., active and no longer recruiting.

Overview Connected4

Overview

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC is a phase 1/2 interventional study registered as NCT05918133 by Biotheus Inc., with 42 participants enrolled, started 2022-07-01 and due to reach its primary completion in 2026-10-30. Interventions recorded: PM8002 and nab-paclitaxel.

Setting

A Phase Ib/II Study of PM8002 Injection Plus Nab-paclitaxel as First Line Therapy for Unresectable, Locally Advanced or Metastatic Triple-negative Breast Cancer

Phase

Phase 1/2

Sponsor

Biotheus Inc.

Registry

Started

2022-07-01

Enrolled

42 enrolled

Connected

Similar pages

Trial
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
Shares PM8002, BioNTech and the tag pipeline.
Trial
PM8002 in the Treatment of Patients With Advanced Solid Tumors
Shares PM8002, BioNTech and the tag pipeline.
Trial
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Shares PM8002, BioNTech and the tag pipeline.
Trial
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
Shares PM8002, BioNTech and the tag pipeline.
Trial
A Study of PM8002 in Combination With Chemotherapy in Patients With NEN
Shares PM8002, BioNTech and the tag pipeline.
Trial
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Shares PM8002, BioNTech, Triple-negative breast cancer (TNBC) and the tag pipeline.
Trial
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Shares PM8002, BioNTech and the tag pipeline.
Trial
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
Shares PM8002, BioNTech and the tag pipeline.

cancers

Metastatic triple-negative breast cancer Triple-negative breast cancer (TNBC)

drugs

Phase 3bispecific antibody

companies

Evidence strength16/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1/2+8
42 enrolled+8
No structured primary endpoint0
Result: active0
No independent replication recorded0

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Link 1,018 registry trials to cancer subtype pages by dri… · diff · file

Sources & links

ClinicalTrials.gov NCT05918133

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Triple-negative breast cancer (TNBC)
Metastatic triple-negative breast cancer

Products

PM8002

Companies

BioNTech

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct05918133/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct05918133.

WebMCP tools registered on this page: onco_search, onco_get_entity.